Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R. (2019) Acromegaly. Nat Rev Dis Primers Mar 5 (1):20

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. https://doi.org/10.1007/s11154-020-09588-z

Article  PubMed  PubMed Central  Google Scholar 

Schmid HA, Schoeffter P (2004) (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47–50. https://doi.org/10.1159/000080741

Article  CAS  PubMed  Google Scholar 

Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. https://doi.org/10.1016/j.mce.2007.09.006

Article  PubMed  Google Scholar 

Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide C2305 Study Group Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2013-2480

Article  PubMed  PubMed Central  Google Scholar 

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide C2402 Study Group Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(14)70169-X

Article  PubMed  Google Scholar 

Fleseriu M, Rusch E, Geer EB (2017) ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. https://doi.org/10.1007/s12020-016-1182-4

Article  PubMed  Google Scholar 

Colao A, Auriemma RS, Pivonello R (2016) The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. https://doi.org/10.1007/s11102-015-0677-y

Article  PubMed  Google Scholar 

Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Luźniak A, Jawiarczyk-Przybyłowska A, Kałużny M (2021) The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2021.633944

Article  PubMed  Google Scholar 

Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol. https://doi.org/10.1530/EJE-19-0762

Article  PubMed  PubMed Central  Google Scholar 

Akirov A, Gorshtein A, Dotan I, Khazen NS, Pauker Y, Gershinsky M, Shimon I (2021) Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine. https://doi.org/10.1007/s12020-021-02782-2

Article  PubMed  Google Scholar 

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2014-2700

Article  PubMed  PubMed Central  Google Scholar 

Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ (2007) Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. https://doi.org/10.1530/eje.1.02341

Article  PubMed  Google Scholar 

World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation part 1—diagnosis and classification of diabetes mellitus. World Health Organization, Geneva

Google Scholar 

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. https://doi.org/10.1007/BF00280883

Article  CAS  PubMed  Google Scholar 

Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB (2000) Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 47(3):177–184. https://doi.org/10.1016/s0168-8227(99)00116-3

Article  CAS  PubMed  Google Scholar 

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group (2016) ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. https://doi.org/10.1093/eurheartj/ehw272

Article  PubMed  PubMed Central  Google Scholar 

Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF (2012) Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2011-3213

Article  PubMed  PubMed Central  Google Scholar 

Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746–3756. https://doi.org/10.1210/jc.2009-0941

Article  CAS  PubMed  Google Scholar 

Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, Santos E, Magalhães J, Wildemberg LE (2023) Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years’ single-center real-world experience. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgad378

Article  PubMed  PubMed Central  Google Scholar 

Araujo-Castro M, Pian H, Ruz-Caracuel I, Acitores Cancela A, Pascual-Corrales E, Rodríguez Berrocal V. (2021 ) Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas. Endocr Connect. Jan;10(1):102–109;cStevenaert A, Beckers A. Presurgical Octreotide: treatment in acromegaly. Metabolism. 1996 Aug;45(8 Suppl 1):72–4

Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2004-1093

Article  PubMed  Google Scholar 

Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J (2008) Preoperative Octreotide Treatment of Acromegaly study group. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2008-0315

Article  PubMed  Google Scholar 

Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. https://doi.org/10.1530/EC-20-0361

Article  PubMed  PubMed Central  Google Scholar 

Corica G, Pirchio R, Milioto A, Nista F, Arecco A, Mattioli L, Auriemma RS, Cocchiara F, Pivonello R, Colao A, Ferone D, Gatto F (2023) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02186-1

Article  PubMed  Google Scholar 

Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F, Pipeleers DG, Eizirik DL (1999) Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. https://doi.org/10.1016/s0006-2952(99)00010-6

Article  PubMed  Google Scholar 

Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plöckinger U, Strowski MZ (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2006-1578

Article  PubMed  PubMed Central  Google Scholar 

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453. https://doi.org/10.1210/jc.2013-1771

Article  CAS  PubMed  Google Scholar 

Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2013.12.011